Eli Lilly and Co. said it will not submit its osteoporosis medicine arzoxifene for FDA review after the drug failed to meet certain clinical goals in a Phase III clinical trial. The Indianapolis drug firm will take an after-tax charge of $35 million to $45 million for discontinuing arzoxifene's development.

Related Summaries